Home > Compound List > Product Information
Chromium picolinate_Molecular_structure_CAS_14639-25-9)
Click picture or here to close

Chromium picolinate

Catalog No. C4124 Name Sigma Aldrich
CAS Number 14639-25-9 Website http://www.sigmaaldrich.com
M. F. C18H12CrN3O6 Telephone 1-800-521-8956
M. W. 418.30048 Fax
Purity ≥98% (HPLC) Email
Storage Chembase ID: 105616

SYNONYMS

IUPAC name
bis(pyridine-2-carbonyloxy)chromio pyridine-2-carboxylate
IUPAC Traditional name
bis(pyridine-2-carbonyloxy)chromio pyridine-2-carboxylate
Synonyms
CrPic
Cr(pic)3

DATABASE IDS

CAS Number 14639-25-9
MDL Number MFCD00068715

PROPERTIES

Biological Source from synthetic
Empirical Formula (Hill Notation) C18H12CrN3O6
Loss on Drying ≤5% loss on drying
Purity ≥98% (HPLC)
GHS Pictograms GHS07
GHS Signal Word Warning
GHS Hazard statements H315-H319-H335
European Hazard Symbols Irritant Irritant (Xi)
MSDS Link Download
GHS Precautionary statements P261-P305 + P351 + P338
Risk Statements 36/37/38
Safety Statements 26-36
Storage Temperature room temp
German water hazard class 3

DETAILS

Description (English)
Biochem/physiol Actions
Chromium picolinate (CrPic) is a supplemental or alternative medication for type 2 diabetes. Experimental evidence shows the effect of CrPic on glucose uptake through the activation of p38 MAPK.1 Chromium is thought to potentiate the action of insulin, leading to increased insulin sensitivity in type 2 diabetes.2
General description
Chromium picolinate is a supplemental or alternative medication for type 2 diabetes and an anti-diabetic mechanisms of CrPic in insulin-resistant 3T3-L1 adipocytes.
Description (简体中文)
Biochem/physiol Actions
Chromium picolinate (CrPic) is a supplemental or alternative medication for type 2 diabetes. Experimental evidence shows the effect of CrPic on glucose uptake through the activation of p38 MAPK.1 Chromium is thought to potentiate the action of insulin, leading to increased insulin sensitivity in type 2 diabetes.2
General description
Chromium picolinate is a supplemental or alternative medication for type 2 diabetes and an anti-diabetic mechanisms of CrPic in insulin-resistant 3T3-L1 adipocytes.

REFERENCES